Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 891

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 4
Chunk 891
---
 majority of independent directors for election by stockholders or appointment by
    the board of directors as the case may be, pursuant to our bylaws and consistent with the board of director’s evidence for
    selecting new directors;

    ●
    review
    the suitability for continued service as a director of each member of the board of directors when his or her term expires or when
    he or she has a significant change in status;

    ●
    review
    annually the composition of the board of directors and to review periodically the size of the board of directors;

    ●
    make
    recommendations on the frequency and structure of board of directors meetings or any other aspect of procedures of the board of directors;

    ●
    make
    recommendations regarding the chairmanship and composition of standing committees and monitor their functions;

    ●
    review
    annually committee assignments and chairmanships;

    ●
    recommend
    the establishment of special committees as may be necessary or desirable from time to time; and

    ●
    develop
    and periodically review corporate governance procedures and consider any other corporate governance issue.

Code
of Ethics

We
have adopted a code of ethics that applies to all of our executive officers, directors and employees. The code of ethics codifies the
business and ethical principles that govern all aspects of our business. This document will be made available in print, free of charge,
to any stockholder requesting a copy in writing from our secretary at our executive offices in Gaithersburg, Maryland. A copy of our
code of ethics is available on our website at www.shuttlepharma.com.

77

Insider
Trading Policies and Procedures

The
Company has adopted an insider trading policy, as amended and restated on March 10, 2023 (the “Insider Trading Policy”),
overseen by the Company’s corporate secretary, that applies to all (i) directors, (ii) executive officers and (iii) employees who
are exposed to insider information (together, the “Covered Persons”). The Insider Trading Policy prohibits the use of material
non-public information obtained by Covered Persons through their involvement with the Company when making decisions to purchase, sell,
give away or otherwise trade in the Company’s securities or to provide such information to others outside the organization. Under
the Insider Trading Policy, material non-public information includes, among other things, significant changes in the Company’s
prospects, significant write-downs, liquidity problems, changes in management, extraordinary